Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology Forecast 2025-2034

In warm autoimmune hemolytic anemia, premature destruction of healthy red blood cells is caused by the antibodies that are active at body temperature. This autoimmune disease affects around 1 to 3 per 100,000 individuals each year. Warm autoimmune hemolytic anemia is the most common type of autoimmune hemolytic anemia and can occur at any age.

Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology Forecast Report Coverage

The “Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Warm Autoimmune Hemolytic Anemia (wAIHA). It projects the future incidence and prevalence rates of warm autoimmune hemolytic anemia (wAIHA) across various populations. The study covers age and type as major determinants of the warm autoimmune hemolytic anemia (wAIHA)-affected population. The report highlights patterns in the prevalence of warm autoimmune hemolytic anemia (wAIHA) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of warm autoimmune hemolytic anemia (wAIHA) in the 8 major markets.

Regions Covered

• The United States
• The United Kingdom
• France
• Italy
• Spain
• Germany
• Japan
• India

Warm Autoimmune Hemolytic Anemia (wAIHA): Disease Overview

Warm autoimmune hemolytic anemia is a blood disorder characterized by the body's own antibodies attacking and destroying red blood cells. This autoimmune disease is called "warm" because the autoantibodies are active at body temperature. Warm autoimmune hemolytic anemia can be caused by certain medications or conditions but in roughly half of the cases, the cause is unknown. Common symptoms include paleness, weakness, fever, heart murmur, and dark-colored urine, among others.

Warm Autoimmune Hemolytic Anemia (wAIHA): Treatment Overview

For initial treatment, corticosteroids are typically used for patients with warm autoimmune hemolytic anemia. Alternatives include intravenous immunoglobulin, mycophenolate, cyclophosphamide, azathioprine, etc. Studies show in nearly 30% of the patients, a durable remission following initial treatment is seen. However, the rest often suffer a chronic, relapsing course. Fostamatinib, rilzabrutinib, and FcRn inhibitors are some of the promising therapies for wAIHA. Bortezomib, a proteasome inhibitor, is another emerging drug that may help in reducing the production of plasma cells that produce autoantibodies.

Epidemiology

The warm autoimmune hemolytic anemia (wAIHA) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for warm autoimmune hemolytic anemia (wAIHA) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for warm autoimmune hemolytic anemia (wAIHA) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per National Organization for Rare Disorders (NORD), warm autoimmune hemolytic anemia is the most common type of autoimmune hemolytic anemia, affecting around 1 to 4 per 100,000 individuals annually and occurring at any age.
• In warm autoimmune hemolytic anemia, the autoantibodies generated by the body are active at 37 degree Celsius or higher. It accounts for approximately 70 to 80% of all adult autoimmune hemolytic anemia cases and around 50% of pediatric cases.
• According to the Orphanet, warm autoimmune hemolytic anemia is reported to be occur more commonly in women than in men, with female to male ratio estimated to be about 2:1 in adults.
• Idiopathic (primary warm autoimmune hemolytic anemia) accounts for nearly 50% of all warm autoimmune hemolytic anemia cases. Secondary warm autoimmune hemolytic anemia, which is linked with underlying conditions such as chronic lymphocytic leukemia or an autoimmune systemic disease, contributes to the other half of the cases.

Country-wise Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology

The warm autoimmune hemolytic anemia (wAIHA) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of warm autoimmune hemolytic anemia (wAIHA) varies significantly between countries owing to the differences in genetic predispositions, ethnic backgrounds, environmental and geographical factors, healthcare access, and diagnostic capabilities, among others. The prevalence of conditions linked to warm autoimmune hemolytic anemia like autoimmune disorders, lymphoproliferative conditions, or infections can also influence the incidence and presentation of the disease across different regions. In North America and Western Europe, the annual incidence of warm autoimmune hemolytic anemia is reported to be between 1 in 35,000 to 80,000.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of warm autoimmune hemolytic anemia (wAIHA) based on several factors.
• Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of warm autoimmune hemolytic anemia (wAIHA) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of warm autoimmune hemolytic anemia (wAIHA) epidemiology in the 8 major markets?
• What will be the total number of patients with warm autoimmune hemolytic anemia (wAIHA) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of warm autoimmune hemolytic anemia (wAIHA) in the 8 major markets in the historical period?
• Which country will have the highest number of warm autoimmune hemolytic anemia (wAIHA) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of warm autoimmune hemolytic anemia (wAIHA) during the forecast period of 2025-2034?
• What are the currently available treatments for warm autoimmune hemolytic anemia (wAIHA)?
• What are the disease risks, signs, symptoms, and unmet needs of warm autoimmune hemolytic anemia (wAIHA)?

This product will be delivered within 3-5 business days.